Angiodynamics Financials
Angiodynamics (ANGO) reported $320.2M in revenue for fiscal year 2026, up 9.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AngioDynamics is stabilizing its cash burn through a higher-margin, low-capex operating model, not through rapid revenue expansion.
Goodwill dropped from$159.2M in FY2023 to$0 in FY2024, pointing to a balance-sheet reset inside the year of the outsized loss. Because FY2024 revenue still held near$303.9M and FY2026 operating cash flow rebounded to$3.1M , cash conversion is normalizing faster than GAAP earnings after that reset.
FY2026 gross margin reached
Free cash flow turned positive at
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Angiodynamics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Angiodynamics has an operating margin of -12.5%, meaning the company loses $12 on every $100 of revenue. This results in a profitability score of 20/100. This is up from -13.7% the prior year.
Angiodynamics's revenue grew 9.5% year-over-year to $320.2M, a solid pace of expansion. This earns a growth score of 41/100.
Angiodynamics has a moderate D/E ratio of 0.56. This balance of debt and equity financing earns a leverage score of 57/100.
Angiodynamics's current ratio of 2.19 indicates adequate short-term liquidity, earning a score of 62/100. The company can meet its near-term obligations, though with limited headroom.
While Angiodynamics generated $3.1M in operating cash flow, capex of $2.6M consumed most of it, leaving $508K in free cash flow. This results in a low score of 22/100, reflecting heavy capital investment rather than weak cash generation.
Angiodynamics posts a -21.5% return on equity (ROE), meaning it loses $22 for every $100 of shareholders' equity. This results in a returns score of 18/100. This is down from -18.6% the prior year.
Angiodynamics scores 2.72, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($651.8M) relative to total liabilities ($96.3M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Angiodynamics passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Angiodynamics reported a net loss of $36.7M while generating $3.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Angiodynamics generated $320.2M in revenue in fiscal year 2026. This represents an increase of 9.5% from the prior year.
Angiodynamics's EBITDA was -$17.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 19.9% from the prior year.
Angiodynamics reported -$36.7M in net income in fiscal year 2026. This represents a decrease of 8.1% from the prior year.
Angiodynamics earned -$0.88 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 6.0% from the prior year.
Cash & Balance Sheet
Angiodynamics generated $508K in free cash flow in fiscal year 2026, representing cash available after capex. This represents an increase of 103.5% from the prior year.
Angiodynamics held $53.9M in cash as of fiscal year 2026; long-term debt is not reported for that period.
Not reported for fiscal year 2026.
Margins & Returns
Angiodynamics's gross margin was 54.6% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the prior year.
Angiodynamics's operating margin was -12.5% in fiscal year 2026, reflecting core business profitability. This is up 1.2 percentage points from the prior year.
Angiodynamics's net profit margin was -11.5% in fiscal year 2026, showing the share of revenue converted to profit. This is up 0.1 percentage points from the prior year.
Angiodynamics's ROE was -21.5% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 2.9 percentage points from the prior year.
Capital Allocation
Angiodynamics invested $29.4M in research and development in fiscal year 2026. This represents an increase of 12.3% from the prior year.
Angiodynamics repurchased no shares in fiscal year 2026. This represents a decrease of 100.0% from the prior year.
Angiodynamics invested $2.6M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 42.2% from the prior year.
ANGO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $320.2M+9.5% | $292.5M-3.8% | $303.9M-10.3% | $338.8M+7.1% | $316.2M+8.7% | $291.0M+10.2% | $264.2M-2.4% | $270.6M+3.4% | $261.7M-3.0% | $269.8M-23.8% | $353.9M-0.7% | $356.5M+0.6% | $354.4M+3.7% | $341.9M+54.1% | $221.9M |
| Cost of Revenue | $145.3M+7.8% | $134.8M-9.7% | $149.2M-9.3% | $164.5M+9.3% | $150.5M+12.1% | $134.2M+17.9% | $113.9M-0.7% | $114.6M-2.7% | $117.8M-6.4% | $125.8M-29.9% | $179.6M-0.6% | $180.7M+3.7% | $174.3M+0.5% | $173.4M+79.5% | $96.6M |
| Gross Profit | $174.9M+10.9% | $157.7M+1.9% | $154.7M-11.2% | $174.2M+5.1% | $165.7M+5.7% | $156.8M+4.3% | $150.3M-3.7% | $156.0M+8.4% | $143.9M-0.1% | $143.9M-17.4% | $174.3M-0.8% | $175.8M-2.4% | $180.2M+6.9% | $168.5M+34.5% | $125.3M |
| R&D Expenses | $29.4M+12.3% | $26.2M-16.8% | $31.5M+5.5% | $29.9M-2.8% | $30.7M-15.5% | $36.4M+22.6% | $29.7M+5.0% | $28.3M+16.1% | $24.3M+0.8% | $24.1M-3.6% | $25.1M-5.8% | $26.6M-5.4% | $28.1M+7.8% | $26.1M+27.2% | $20.5M |
| SG&A Expenses | $43.7M+3.8% | $42.1M+2.3% | $41.2M+2.9% | $40.0M+4.0% | $38.5M+7.1% | $35.9M-5.2% | $37.9M+8.5% | $34.9M+12.6% | $31.0M-0.5% | $31.1M+1.8% | $30.6M+1.8% | $30.0M+11.6% | $26.9M+3.3% | $26.0M+36.8% | $19.0M |
| Operating Income | -$39.9M+0.1% | -$40.0M+79.2% | -$192.4M-276.0% | -$51.2M-79.8% | -$28.5M+19.3% | -$35.3M+78.9% | -$167.1M-1678.4% | -$9.4M+33.7% | -$14.2M-26.8% | -$11.2M-1197.7% | $1.0M+129.5% | -$3.4M-132.9% | $10.5M+100.1% | $5.2M+200.0% | -$5.2M |
| Interest Expense | N/A | N/A | -$1.6M-159.7% | $2.7M+292.7% | $688K-20.1% | $861K-5.1% | $907K-82.2% | $5.1M+66.5% | $3.1M+7.9% | $2.8M-16.1% | $3.4M+6.0% | $3.2M-12.7% | $3.7M-30.6% | $5.3M+937.6% | $508K |
| Income Tax | $442K+1233.3% | -$39K+99.5% | -$7.3M-265.4% | -$2.0M+41.4% | -$3.4M+24.5% | -$4.5M-234.1% | -$1.3M+62.1% | -$3.6M+67.8% | -$11.0M-52.4% | -$7.2M-118.0% | $40.3M+950.5% | -$4.7M+48.4% | -$9.2M-3116.8% | -$286K+11.2% | -$322K |
| Net Income | -$36.7M-8.1% | -$34.0M+81.6% | -$184.3M-251.5% | -$52.4M-97.5% | -$26.5M+15.9% | -$31.5M+81.1% | -$166.8M-371.9% | $61.3M+275.5% | $16.3M+226.2% | $5.0M+111.5% | -$43.6M-1186.6% | -$3.4M-244.4% | $2.3M+323.3% | -$1.1M+80.3% | -$5.3M |
| EPS (Diluted) | -$0.88-6.0% | -$0.83+81.9% | -$4.59-245.1% | -$1.33-95.6% | -$0.68+17.1% | -$0.82+81.3% | -$4.39-367.7% | $1.64+272.7% | $0.44+214.3% | $0.14+111.6% | -$1.21-1244.4% | -$0.09-228.6% | $0.07+333.3% | -$0.03+85.0% | -$0.20 |
ANGO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $267.2M-4.6% | $280.1M-11.8% | $317.7M-40.4% | $532.6M-3.6% | $552.8M-1.5% | $561.4M-5.5% | $594.2M-29.0% | $836.4M+18.6% | $705.5M-0.4% | $708.0M-2.5% | $726.2M-6.1% | $773.1M-3.2% | $798.6M+1.0% | $790.6M+9.8% | $719.9M |
| Current Assets | $163.4M-2.9% | $168.3M-12.9% | $193.3M+18.2% | $163.5M+14.1% | $143.3M+1.8% | $140.9M-7.9% | $152.9M-51.5% | $315.3M+87.6% | $168.0M+9.2% | $153.9M+5.2% | $146.3M-3.0% | $150.8M+2.6% | $147.0M+4.2% | $141.2M-10.5% | $157.8M |
| Cash & Equivalents | $53.9M-3.6% | $55.9M-26.5% | $76.1M+70.5% | $44.6M+54.8% | $28.8M-40.1% | $48.2M-11.5% | $54.4M-76.1% | $227.6M+207.2% | $74.1M+55.8% | $47.5M+47.0% | $32.3M+75.8% | $18.4M0.0% | $18.4M+14.2% | $16.1M-32.2% | $23.7M |
| Inventory | $52.4M-15.4% | $62.0M+2.3% | $60.6M+9.6% | $55.3M+7.7% | $51.4M+5.7% | $48.6M-18.8% | $59.9M+49.5% | $40.1M+2.0% | $39.3M-27.9% | $54.5M-1.6% | $55.4M-17.8% | $67.4M+9.1% | $61.7M+12.1% | $55.1M-1.3% | $55.8M |
| Accounts Receivable | $48.3M+12.7% | $42.9M-1.7% | $43.6M-17.4% | $52.8M+1.0% | $52.3M+47.7% | $35.4M+13.2% | $31.3M-28.3% | $43.6M+10.6% | $39.4M-11.5% | $44.5M-15.8% | $52.9M-9.5% | $58.4M-5.7% | $62.0M+30.0% | $47.7M+1.7% | $46.9M |
| Goodwill | N/A | N/A | $0-100.0% | $159.2M-20.8% | $201.1M-0.1% | $201.3M+0.4% | $200.5M-42.3% | $347.7M+21.6% | $285.9M-20.8% | $361.3M0.0% | $361.3M0.0% | $361.3M+0.2% | $360.5M+1.4% | $355.6M+15.1% | $309.1M |
| Total Liabilities | $96.3M-0.9% | $97.2M-13.3% | $112.1M-27.4% | $154.3M+20.3% | $128.3M+5.1% | $122.0M-12.5% | $139.3M-37.1% | $221.6M+36.1% | $162.9M-15.6% | $192.9M-11.9% | $219.0M-3.9% | $228.0M-12.9% | $261.7M-1.0% | $264.2M+34.4% | $196.6M |
| Current Liabilities | $74.7M-1.9% | $76.2M-16.4% | $91.2M+8.7% | $83.8M+12.8% | $74.3M+29.1% | $57.6M+11.9% | $51.4M-29.8% | $73.3M+27.9% | $57.3M-19.9% | $71.5M+7.2% | $66.7M+10.3% | $60.5M-8.2% | $65.9M+4.8% | $62.9M+17.0% | $53.8M |
| Long-Term Debt | N/A | N/A | $0-100.0% | $49.8M+99.3% | $25.0M | N/A | N/A | $124.4M+43.6% | $86.6M-5.1% | $91.3M | N/A | N/A | $137.7M+2.0% | $135.0M-5.3% | $142.5M |
| Total Equity | $170.8M-6.6% | $183.0M-11.0% | $205.6M-45.7% | $378.3M-10.9% | $424.5M-3.4% | $439.5M-3.4% | $454.9M-26.0% | $614.8M+13.3% | $542.6M+5.4% | $515.0M+1.5% | $507.2M-6.9% | $545.1M+1.5% | $536.9M+2.0% | $526.3M+0.6% | $523.3M |
| Retained Earnings | -$465.9M-8.6% | -$429.2M-8.6% | -$395.2M-87.4% | -$210.9M-33.1% | -$158.4M-20.1% | -$131.9M-31.4% | -$100.3M-250.9% | $66.5M+1195.9% | $5.1M+146.6% | -$11.0M+31.3% | -$16.0M-158.1% | $27.6M-10.9% | $31.0M+8.2% | $28.6M-3.5% | $29.7M |
ANGO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.1M+130.5% | -$10.1M+64.0% | -$28.2M-36200.0% | $78K+101.1% | -$7.2M-129.9% | $24.1M+265.5% | -$14.6M-138.9% | $37.4M-9.3% | $41.3M-25.9% | $55.7M+23.3% | $45.2M+76.0% | $25.7M+4.1% | $24.7M-7.4% | $26.7M+129.7% | $11.6M |
| Capital Expenditures | $2.6M-42.2% | $4.5M+77.3% | $2.5M-33.9% | $3.8M-11.3% | $4.3M-17.2% | $5.2M-28.3% | $7.2M+132.0% | $3.1M+30.4% | $2.4M-20.3% | $3.0M+29.0% | $2.3M-79.6% | $11.4M+1.9% | $11.2M-7.8% | $12.1M+386.4% | $2.5M |
| Free Cash Flow | $508K+103.5% | -$14.6M+52.4% | -$30.7M-721.5% | -$3.7M+67.5% | -$11.5M-160.8% | $18.9M+186.8% | -$21.8M-163.5% | $34.3M-11.8% | $38.9M-26.3% | $52.7M+23.0% | $42.9M+199.9% | $14.3M+5.9% | $13.5M-7.0% | $14.5M+59.5% | $9.1M |
| Investing Cash Flow | -$5.9M+41.6% | -$10.2M-108.2% | $123.7M+1369.4% | -$9.7M+49.5% | -$19.3M-40.8% | -$13.7M+78.4% | -$63.3M-176.7% | $82.6M+2358.0% | -$3.7M-43.3% | -$2.6M+66.3% | -$7.6M+40.6% | -$12.7M+22.6% | -$16.4M+26.0% | -$22.2M+87.4% | -$176.2M |
| Financing Cash Flow | $564K+321.2% | -$255K+99.6% | -$64.2M-352.7% | $25.4M+230.9% | $7.7M+145.2% | -$17.0M+82.2% | -$95.2M-380.7% | $33.9M+393.7% | -$11.6M+69.6% | -$38.0M-60.5% | -$23.7M-126.1% | -$10.5M+25.3% | -$14.0M-123.0% | -$6.3M-104.4% | $142.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Share Buybacks | $0-100.0% | $1.7M | $0 | $0 | N/A | N/A | N/A | $0 | $0-100.0% | $13.6M | $0 | $0 | $0 | $0-100.0% | $2.1M |
ANGO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.6%+0.7pp | 53.9%+3.0pp | 50.9%-0.5pp | 51.4%-1.0pp | 52.4%-1.5pp | 53.9%-3.0pp | 56.9%-0.8pp | 57.6%+2.7pp | 55.0%+1.6pp | 53.4%+4.1pp | 49.3%-0.1pp | 49.3%-1.5pp | 50.8%+1.5pp | 49.3%-7.2pp | 56.5% |
| Operating Margin | -12.5%+1.2pp | -13.7%+49.7pp | -63.3%-48.2pp | -15.1%-6.1pp | -9.0%+3.1pp | -12.1%+51.1pp | -63.3%-59.8pp | -3.5%+1.9pp | -5.4%-1.3pp | -4.1%-4.4pp | 0.3%+1.3pp | -1.0%-3.9pp | 3.0%+1.4pp | 1.5%+3.9pp | -2.4% |
| Net Margin | -11.5%+0.1pp | -11.6%+49.0pp | -60.7%-45.2pp | -15.5%-7.1pp | -8.4%+2.4pp | -10.8%+52.3pp | -63.1%-85.8pp | 22.7%+16.4pp | 6.2%+4.4pp | 1.9%+14.2pp | -12.3%-11.4pp | -0.9%-1.6pp | 0.7%+1.0pp | -0.3%+2.1pp | -2.4% |
| Return on Equity | -21.5%-2.9pp | -18.6%+71.1pp | -89.7%-75.8pp | -13.9%-7.6pp | -6.3%+0.9pp | -7.2%+29.5pp | -36.7%-46.7pp | 10.0%+7.0pp | 3.0%+2.0pp | 1.0%+9.6pp | -8.6%-8.0pp | -0.6%-1.1pp | 0.4%+0.6pp | -0.2%+0.8pp | -1.0% |
| Return on Assets | -13.8%-1.6pp | -12.1%+45.9pp | -58.0%-48.2pp | -9.8%-5.1pp | -4.8%+0.8pp | -5.6%+22.4pp | -28.1%-35.4pp | 7.3%+5.0pp | 2.3%+1.6pp | 0.7%+6.7pp | -6.0%-5.6pp | -0.4%-0.7pp | 0.3%+0.4pp | -0.1%+0.6pp | -0.7% |
| Current Ratio | 2.190.0x | 2.21+0.1x | 2.12+0.2x | 1.950.0x | 1.93-0.5x | 2.45-0.5x | 2.97-1.3x | 4.30+1.4x | 2.93+0.8x | 2.150.0x | 2.19-0.3x | 2.49+0.3x | 2.230.0x | 2.24-0.7x | 2.93 |
| Debt-to-Equity | 0.560.0x | 0.53+0.5x | 0.00-0.1x | 0.13+0.1x | 0.06-0.2x | 0.280.0x | 0.31+0.1x | 0.200.0x | 0.160.0x | 0.18-0.3x | 0.430.0x | 0.42+0.2x | 0.260.0x | 0.260.0x | 0.27 |
| FCF Margin | 0.2%+5.1pp | -5.0%+5.1pp | -10.1%-9.0pp | -1.1%+2.5pp | -3.6%-10.1pp | 6.5%+14.8pp | -8.3%-20.9pp | 12.7%-2.2pp | 14.9%-4.7pp | 19.6%+7.4pp | 12.1%+8.1pp | 4.0%+0.2pp | 3.8%-0.4pp | 4.3%+0.1pp | 4.1% |
Similar Companies
Where Angiodynamics Ranks
Frequently Asked Questions
What is Angiodynamics's annual revenue?
Angiodynamics (ANGO) reported $320.2M in total revenue for fiscal year 2026. This represents a 9.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Angiodynamics's revenue growing?
Angiodynamics (ANGO) revenue grew by 9.5% year-over-year, from $292.5M to $320.2M in fiscal year 2026.
Is Angiodynamics profitable?
No, Angiodynamics (ANGO) reported a net income of -$36.7M in fiscal year 2026, with a net profit margin of -11.5%.
What is Angiodynamics's EBITDA?
Angiodynamics (ANGO) had EBITDA of -$17.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Angiodynamics's gross margin?
Angiodynamics (ANGO) had a gross margin of 54.6% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Angiodynamics's operating margin?
Angiodynamics (ANGO) had an operating margin of -12.5% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Angiodynamics's net profit margin?
Angiodynamics (ANGO) had a net profit margin of -11.5% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Angiodynamics's return on equity (ROE)?
Angiodynamics (ANGO) has a return on equity of -21.5% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Angiodynamics's free cash flow?
Angiodynamics (ANGO) generated $508K in free cash flow during fiscal year 2026. This represents a 103.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Angiodynamics's operating cash flow?
Angiodynamics (ANGO) generated $3.1M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Angiodynamics's total assets?
Angiodynamics (ANGO) had $267.2M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Angiodynamics's capital expenditures?
Angiodynamics (ANGO) invested $2.6M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Angiodynamics spend on research and development?
Angiodynamics (ANGO) invested $29.4M in research and development during fiscal year 2026.
What is Angiodynamics's current ratio?
Angiodynamics (ANGO) had a current ratio of 2.19 as of fiscal year 2026, which is generally considered healthy.
What is Angiodynamics's debt-to-equity ratio?
Angiodynamics (ANGO) had a debt-to-equity ratio of 0.56 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Angiodynamics's return on assets (ROA)?
Angiodynamics (ANGO) had a return on assets of -13.8% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Angiodynamics's Altman Z-Score?
Angiodynamics (ANGO) has an Altman Z-Score of 2.72, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Angiodynamics's Piotroski F-Score?
Angiodynamics (ANGO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Angiodynamics's earnings high quality?
Angiodynamics (ANGO) reported a net loss of $36.7M while generating $3.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Angiodynamics?
Angiodynamics (ANGO) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.